Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J: Prevalence of spondylarthropathies in HLA B27-positive and -negative blood donors. Arthritis Rheum. 1998, 41: 58-67. 10.1002/1529-0131(199801)41:1<58::AID-ART8>3.3.CO;2-7.
PubMed
CAS
Google Scholar
Brandt J, Bollow M, Haberle J, Rudwaleit M, Eggens U, Distler A, Hamm B, Sieper J: Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy. Rheumatology (Oxford). 1999, 38: 831-836. 10.1093/rheumatology/38.9.831.
CAS
Google Scholar
Gran JT, Husby G, Hordvik M: Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann Rheum Dis. 1985, 44: 359-367.
PubMed
CAS
PubMed Central
Google Scholar
Saraux A, Guedes C, Allain J, Devauchelle V, Valls I, Lamour A, Guillemin F, Youinou P, Le Goff P: Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Société de Rhumatologie de l'Ouest. J Rheumatol. 1999, 26: 2622-2627.
PubMed
CAS
Google Scholar
Zink A, Braun J, Listing J, Wollenhaupt J: Disability and handicap in rheumatoid arthritis and ankylosing spondylitis–results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol. 2000, 27: 613-622.
PubMed
CAS
Google Scholar
Zink A, Listing J, Klindworth C, Zeidler H: The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients. Ann Rheum Dis. 2001, 60: 199-206. 10.1136/ard.60.3.199.
PubMed
CAS
PubMed Central
Google Scholar
Boonen A, Chorus A, Miedema H, van Der Heijde D, van Der Tempel H, van der Linden S: Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis. 2001, 60: 353-358. 10.1136/ard.60.4.353.
PubMed
CAS
PubMed Central
Google Scholar
Boonen A, van Der Heijde D, Landewe R, Spoorenberg A, Schouten H, Rutten-Van Molken M, Guillemin F, Dougados M, Mielants H, de Vlam K, van Der Tempel H, van Der Linden S: Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis. 2002, 61: 429-437. 10.1136/ard.61.5.429.
PubMed
CAS
PubMed Central
Google Scholar
Ward MM: Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res. 1999, 12: 247-255. 10.1002/1529-0131(199908)12:4<247::AID-ART3>3.3.CO;2-8.
PubMed
CAS
Google Scholar
van Tubergen A, Coenen J, Landewe R, Spoorenberg A, Chorus A, Boonen A, van der Linden S, van der Heijde D: Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum. 2002, 47: 8-16. 10.1002/art1.10179.
PubMed
Google Scholar
van Tubergen A, Landewe R, van der Heijde D, Hidding A, Wolter N, Asscher M, Falkenbach A, Genth E, The HG, van der Linden S: Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum. 2001, 45: 430-438. 10.1002/1529-0131(200110)45:5<430::AID-ART362>3.0.CO;2-F.
PubMed
CAS
Google Scholar
Santos H, Brophy S, Calin A: Exercise in ankylosing spondylitis: how much is optimum?. J Rheumatol. 1998, 25: 2156-2160.
PubMed
CAS
Google Scholar
Amor B, Dougados M, Mijiyawa M: Criteria for the classification of spondylarthropathies. Rev Rhum Mal Osteoartic. 1990, 57: 85-89.
PubMed
CAS
Google Scholar
Leirisalo-Repo M: Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheum Dis Clin North Am. 1998, 24: 737-751.
PubMed
CAS
Google Scholar
Amor B, Santos RS, Nahal R, Listrat V, Dougados M: Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol. 1994, 21: 1883-1887.
PubMed
CAS
Google Scholar
Amor B, Dougados M, Khan MA: Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am. 1995, 21: 117-128.
PubMed
CAS
Google Scholar
Calin A, Elswood J: A prospective nationwide cross-sectional study of NSAID usage in 1331 patients with ankylosing spondylitis. J Rheumatol. 1990, 17: 801-803.
PubMed
CAS
Google Scholar
Toussirot E, Wendling D: Current guidelines for the drug treatment of ankylosing spondylitis. Drugs. 1998, 56: 225-240.
PubMed
CAS
Google Scholar
Dougados M, Gueguen A, Nakache JP, Velicitat P, Veys EM, Zeidler H, Calin A: Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford). 1999, 38: 235-244. 10.1093/rheumatology/38.3.235.
CAS
Google Scholar
Dougados M, Behier JM, Jolchine I, Calin A, van der Heijde D, Olivieri I, Zeidler H, Herman H: Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal anti-inflammatory drug. Arthritis Rheum. 2001, 44: 180-185. 10.1002/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K.
PubMed
CAS
Google Scholar
Porter RW, Ralston SH: Pharmacological management of back pain syndromes. Drugs. 1994, 48: 189-198.
PubMed
CAS
Google Scholar
Koh WH, Pande I, Samuels A, Jones SD, Calin A: Low dose amitriptyline in ankylosing spondylitis: a short term, double blind, placebo controlled study. J Rheumatol. 1997, 24: 2158-2161.
PubMed
CAS
Google Scholar
Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, Zeidler H, Kvien TK, Olivieri I, Dijkmans B, et al: Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 1995, 38: 618-627.
PubMed
CAS
Google Scholar
Clegg DO, Reda DJ, Abdellatif M: Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999, 42: 2325-2329. 10.1002/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C.
PubMed
CAS
Google Scholar
Nissila M, Lehtinen K, Leirisalo-Repo M, Luukkainen R, Mutru O, Yli-Kerttula U: Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum. 1988, 31: 1111-1116.
PubMed
CAS
Google Scholar
Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, Budiman-Mak E, Blackburn WD, Vasey FB, Mahowald ML, Cush JJ, Schumacher HR, Silverman SL, Alepa FP, Luggen ME, Cohen MR, Makkena R, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. Arthritis Rheum. 1996, 39: 2013-2020.
PubMed
CAS
Google Scholar
Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Banares A: Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye. 2000, 14: 340-343.
PubMed
Google Scholar
Handler RP: Favorable results using methotrexate in the treatment of patients with ankylosing spondylitis. Arthritis Rheum. 1989, 32: 234-
PubMed
CAS
Google Scholar
Creemers MC, Franssen MJ, van de Putte LB, Gribnau FW, van Riel PL: Methotrexate in severe ankylosing spondylitis: an open study. J Rheumatol. 1995, 22: 1104-1107.
PubMed
CAS
Google Scholar
Biasi D, Carletto A, Caramaschi P, Pacor ML, Maleknia T, Bambara LM: Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol. 2000, 19: 114-117. 10.1007/s100670050027.
PubMed
CAS
Google Scholar
Sampaio-Barros PD, Costallat LT, Bertolo MB, Neto JF, Samara AM: Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol. 2000, 29: 160-162. 10.1080/030097400750002021.
PubMed
CAS
Google Scholar
Ostendorf B, Specker C, Schneider M: Methotrexate lacks efficacy in the treatment of severe ankylosing spondylitis compared to psoriatic arthritis and rheumatoid arthritis. J Clin Rheumatol. 1998, 4: 129-136.
PubMed
CAS
Google Scholar
Roychowdhury B, Bindey-Bagot S, Hunt J, Tunn EJ: Methotrexate in severe ankylosing spondylitis – a randomized placebo-controlled study [abstract]. Rheumatology. 2001, 40 (suppl 1): S43-
Google Scholar
Ward MM, Kuzis S: Treatment used by patients with with ankylosing spondylitis: comparison with treatment preferences by rheumatologists. J Clin Rheumatol. 1999, 5: 1-8.
PubMed
CAS
Google Scholar
Durez P, Horsmans Y: Dramatic response after an intravenous loading dose of azathioprine in one case of severe and refractory ankylosing spondylitis. Rheumatology (Oxford). 2000, 39: 182-184. 10.1093/rheumatology/39.2.182.
CAS
Google Scholar
Salvarani C, Macchioni P, Olivieri I, Marchesoni A, Cutolo M, Ferraccioli G, Cantini F, Salaffi F, Padula A, Lovino C, Dovigo L, Bordin G, Davoli C, Pasero G, Alberighi OD: A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol. 2001, 28: 2274-2282.
PubMed
CAS
Google Scholar
Gonzalez S, Martinez-Borra J, Lopez-Larrea C: Immunogenetics, HLA-B27 and spondyloarthropathies. Curr Opin Rheumatol. 1999, 11: 257-264. 10.1097/00002281-199907000-00006.
PubMed
CAS
Google Scholar
Chang Lee, Man Ahn, Eun Lee, Jung Shin, Mon Ai, Yoo Cho, Bin Yoo Hee, Moon B: Enhanced expession of glucocorticoid receptor messenger RNA in peripheral blood mononuclear cells of patients with ankylosing spondylitis [abstract]. Arthritis Rheum. 2001, 45: S238-
Google Scholar
Tryk A, Schneider U, Berki T, Burmester G, Krause A, Scheffold A, Buttgereit F: Membrane glucocorticoid receptor expression on peripheral blood mononuclear cells of patients with ankylosing spondylitis [abstract]. Arthritis Rheum. 2001, 45: S237-
Google Scholar
Mintz G, Enriquez RD, Mercado U, Robles EJ, Jimenez FJ, Gutierrez G: Intravenous methylprednisolone pulse therapy in severe ankylosing spondylitis. Arthritis Rheum. 1981, 24: 734-736.
PubMed
CAS
Google Scholar
Richter MB, Woo P, Panayi GS, Trull A, Unger A, Shepherd P: The effects of intravenous pulse methylprednisolone on immunological and inflammatory processes in ankylosing spondylitis. Clin Exp Immunol. 1983, 53: 51-59.
PubMed
CAS
PubMed Central
Google Scholar
Peters ND, Ejstrup L: Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. Scand J Rheumatol. 1992, 21: 134-138.
PubMed
CAS
Google Scholar
Yoshida S, Motai Y, Hattori H, Yoshida H, Torikai K: A case of HLA-B27 negative ankylosing spondylitis treated with methyl-prednisolone pulse therapy. J Rheumatol. 1993, 20: 1805-1806.
PubMed
CAS
Google Scholar
Mercado U: The use of methylprednisolone pulse therapy in a severe case of HLA-B27 negative ankylosing spondylitis. J Rheumatol. 1994, 21: 1582-1583.
PubMed
CAS
Google Scholar
Plant MJ, Borg AA, Dziedzic K, Saklatvala J, Dawes PT: Radiographic patterns and response to corticosteroid hip injection. Ann Rheum Dis. 1997, 56: 476-480.
PubMed
CAS
PubMed Central
Google Scholar
Maugars Y, Mathis C, Berthelot JM, Charlier C, Prost A: Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Br J Rheumatol. 1996, 35: 767-770.
PubMed
CAS
Google Scholar
Braun J, Bollow M, Seyrekbasan F, Haberle HJ, Eggens U, Mertz A, Distler A, Sieper J: Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol. 1996, 23: 659-664.
PubMed
CAS
Google Scholar
Luukkainen R, Nissila M, Asikainen E, Sanila M, Lehtinen K, Alanaatu A, Kautiainen H: Periarticular corticosteroid treatment of the sacroiliac joint in patients with seronegative spondyl-arthropathy. Clin Exp Rheumatol. 1999, 17: 88-90.
PubMed
CAS
Google Scholar
Weiss HA, Darby SC, Doll R: Cancer mortality following X-ray treatment of ankylosing spondylitis. Int J Cancer. 1994, 59: 327-338.
PubMed
CAS
Google Scholar
Weiss HA, Darby SC, Fearn T, Doll R: Leukemia mortality after X-ray treatment for ankylosing spondylitis. Radiat Res. 1995, 142: 1-11.
PubMed
CAS
Google Scholar
Koehler L, Kuipers JG, Zeidler H: Managing seronegative spondarthritides. Rheumatology (Oxford). 2000, 39: 360-368. 10.1093/rheumatology/39.4.360.
CAS
Google Scholar
Schmitt E, Ruckbeil C, Wick RR: Long-term clinical investigation of patients with ankylosing spondylitis treated with 224 Ra. Health Physics. 1983, 44 (suppl 1): S197-202.
Google Scholar
Wick RR, Nekolla EA, Gossner W, Kellerer AM: Late effects in ankylosing spondylitis patients treated with 224Ra. Radiat Res. 1999, 152 (suppl 6): S8-S11.
PubMed
CAS
Google Scholar
Braun J, Lemmel M, Manger B, Rau R, Sörensen H, Sieper J: Therapy of ankylosing spondylitis with Radiumchloride. Z Rheumatol. 2001, 60: 74-83. 10.1007/s003930170077.
PubMed
CAS
Google Scholar
Ueo T, Kobori K, Okumura H, Ito K, Yoshida H, Norioka M, Shimizu K, Yamamuro T: Effectiveness of lymphocytapheresis in a patient with ankylosing spondylitis. Transfus Sci. 1990, 11: 97-101.
PubMed
CAS
Google Scholar
Jantunen E, Myllykangas-Luosujarvi R, Kaipiainen-Seppanen O, Nousiainen T: Autologous stem cell transplantation in a lymphoma patient with a long history of ankylosing spondylitis. Rheumatology (Oxford). 2000, 39: 563-564. 10.1093/rheumatology/39.5.563.
CAS
Google Scholar
Koch B, Kranzhofer N, Pfreundschu M, Pees HW, Trumper L: First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000, 26: 673-675. 10.1038/sj.bmt.1702565.
PubMed
CAS
Google Scholar
Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD, Heffernan M, Reitsma DJ: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 1996, 335: 1785-1791. 10.1056/NEJM199612123352401.
PubMed
CAS
Google Scholar
Maksymowych WP, Jhangri GS, Leclercq S, Skeith K, Yan A, Russell AS: An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol. 1998, 25: 714-717.
PubMed
CAS
Google Scholar
Maksymowych WP, Lambert R, Jhangri GS, Leclercq S, Chiu P, Wong B, Aaron S, Russell AS: Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol. 2001, 28: 144-155.
PubMed
CAS
Google Scholar
Cooper C, Carbone L, Michet CJ, Atkinson EJ, O'Fallon M, Melton LJ: Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol. 1994, 21: 1877-1882.
PubMed
CAS
Google Scholar
Maksymowych WP, Fitzgerald A, LeClercq S, Chiu P, Yan A, Skeith K, Aaron S, Homik J, Davis P, Sholter D, Jhangri GS, Russell AS: A 6 month randomized double-blinded dose response comparison of i.v. pamidronate (60 mg vs 10 mg) in the treatment of NSAID-refractory ankylosing spondylitis (AS). Arthritis Rheum. 2002, 46: 766-773. 10.1002/art.10139.
PubMed
CAS
Google Scholar
Richardson P, Hideshima T, Anderson K: Thalidomide: emerging role in cancer medicine. Annu Rev Med. 2002, 53: 629-657. 10.1146/annurev.med.53.082901.104043.
PubMed
CAS
Google Scholar
Marriott JB, Muller G, Dalgleish AG: Thalidomide as an emerging immunotherapeutic agent. Immunol Today. 1999, 20: 538-540. 10.1016/S0167-5699(99)01531-5.
PubMed
CAS
Google Scholar
Breban M, Gombert B, Amor B, Dougados M: Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum. 1999, 42: 580-581. 10.1002/1529-0131(199904)42:3<580::AID-ANR27>3.3.CO;2-4.
PubMed
CAS
Google Scholar
Huang F, Gu J, Zhao W, et al: A one year open label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum. 2002,
Google Scholar
Huang F, Gu J, Braun J, Yu D: Identifying the targets of thalidomide and anti-TNFα antibody treatments in ankylosing spondylitis [abstract]. Arthritis Rheum. 2000, 43: S396-
Google Scholar
Ginsburg PM, Dassopoulos T, Ehrenpreis ED: Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanism and clinical literature. Ann Med. 2001, 33: 516-525.
PubMed
CAS
Google Scholar
Huizinga TW, Dijkmans BA, van der Velde EA, van de Pouw Kraan TC, Verweij CL, Breedveld FC: An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann Rheum Dis. 1996, 55: 833-836.
PubMed
CAS
PubMed Central
Google Scholar
Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, et al: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993, 36: 1681-1690.
PubMed
CAS
Google Scholar
Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994, 344: 1105-1110. 10.1016/S0140-6736(94)90628-9.
PubMed
CAS
Google Scholar
Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN: Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet. 1994, 344: 1125-1127. 10.1016/S0140-6736(94)90632-7.
PubMed
CAS
Google Scholar
Maini RN, Elliott MJ, Brennan FM, Williams RO, Chu CQ, Paleolog E, Charles PJ, Taylor PC, Feldmann M: Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev. 1995, 144: 195-223.
PubMed
CAS
Google Scholar
Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75) -Fc fusion protein. N Engl J Med. 1997, 337: 141-148. 10.1056/NEJM199707173370301.
PubMed
CAS
Google Scholar
Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000, 343: 1594-1602. 10.1056/NEJM200011303432202.
PubMed
CAS
Google Scholar
Braun J, Khan MA, Sieper J: Enthesitis and ankylosis in spondyloarthropathy: what is the target of the immune response?. Ann Rheum Dis. 2000, 59: 985-994. 10.1136/ard.59.12.985.
PubMed
CAS
PubMed Central
Google Scholar
Braun J, Bollow M, Eggens U, Konig H, Distler A, Sieper J: Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum. 1994, 37: 1039-1045.
PubMed
CAS
Google Scholar
Braun J, Bollow M, Sieper J: Radiology and pathology of the spondyloarthropathies. Rheum Dis Clin N Am. 1998, 24: 697-735.
CAS
Google Scholar
McGonagle D, Gibbon W, O'Connor P, Green M, Pease C, Emery P: Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum. 1998, 41: 694-700. 10.1002/1529-0131(199804)41:4<694::AID-ART17>3.0.CO;2-#.
PubMed
CAS
Google Scholar
Francois RJ, Gardner DL, Degrave EJ, Bywaters EG: Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis Rheum. 2000, 43: 2011-2024. 10.1002/1529-0131(200009)43:9<2011::AID-ANR12>3.0.CO;2-Y.
PubMed
CAS
Google Scholar
Bollow M, Fischer T, Reibhauer H, Sieper J, Hamm B, Braun J: T cells and macrophages predominate in early and active sacroiliitis as detected by magnetic resonance imaging in spondyloarthropathies. Ann Rheum Dis. 2000, 59: 135-140. 10.1136/ard.59.2.135.
PubMed
CAS
PubMed Central
Google Scholar
Laloux L, Voisin MC, Allain J, Martin N, Kerboull L, Chevalier X, Claudepierre P: Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis. 2001, 60: 316-321. 10.1136/ard.60.4.316.
PubMed
CAS
PubMed Central
Google Scholar
Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, Eggens U, Distler A, Sieper J: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995, 38: 499-505.
PubMed
CAS
Google Scholar
Mielants H, Veys EM: HLA B27-related arthritis and bowel inflammation: Sulfasalazine in HLA B27-related arthritis. J Rheumatol. 1985, 12: 287-293.
PubMed
CAS
Google Scholar
Mielants H, Veys EM, Goemaere S, Cuvelier C, De Vos M: A prospective study of patients with spondyloarthropathy with special reference to HLA-B27 and to gut histology. J Rheumatol. 1993, 20: 1353-1358.
PubMed
CAS
Google Scholar
Sandborn WJ: Anti-tumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety. Inflamm Bowel Dis. 1999, 5: 119-133.
PubMed
CAS
Google Scholar
Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001, 121: 1088-1094.
PubMed
CAS
Google Scholar
Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK: Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001, 7: 83-88. 10.1097/00054725-200105000-00001.
PubMed
CAS
Google Scholar
Lichtenstein GR: Is infliximab effective for induction of remission in patients with ulcerative colitis?. Inflamm Bowel Dis. 2001, 7: 89-93. 10.1097/00054725-200105000-00002.
PubMed
CAS
Google Scholar
Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H: Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet. 2000, 356: 1821-1822. 10.1016/S0140-6736(00)03239-6.
PubMed
CAS
Google Scholar
Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000, 356: 385-390. 10.1016/S0140-6736(00)02530-7.
PubMed
CAS
Google Scholar
Antoni C, Dechant C, Lorenz HM, Wendler J, Ogilvie A, Lueftl M, Kalden-Nemeth D, Kalden JR, Manger B: Open-label study of infliximab treatment for psoriatic arthritis: Clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Care Res. 2002,
Google Scholar
Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001, 357: 1842-1847. 10.1016/S0140-6736(00)04954-0.
PubMed
CAS
Google Scholar
Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, Lueftl M: Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol. 2001, 144: 587-589. 10.1046/j.1365-2133.2001.04089.x.
PubMed
CAS
Google Scholar
Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Sieper J, Braun J: Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 2000, 43: 1346-1352. 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E.
PubMed
CAS
Google Scholar
Garrett S, Jenkinson TR, Kennedy LG, Whitelock HC, Gaisford P, Calin A: A new approach to defining disease status in ankylosing spondylitis. The Bath AS disease activity index. J Rheumatol. 1994, 21: 2286-2291.
PubMed
CAS
Google Scholar
Brandt J, Haibel H, Reddig J, Sieper J, Braun J: Treatment of patients with severe ankylosing spondylitis with infliximab – a one year follow up. Arthritis Rheum. 2001, 44 (12): 2936-2937. 10.1002/1529-0131(200112)44:12<2936::AID-ART483>3.0.CO;2-M.
PubMed
CAS
Google Scholar
Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM: Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000, 59: 428-433. 10.1136/ard.59.6.428.
PubMed
CAS
PubMed Central
Google Scholar
Stone M, Salonen D, Lax M, Payne U, Lapp V, Inman R: Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol. 2001, 28: 1605-1614.
PubMed
CAS
Google Scholar
Maksymowych WP, Jhangri GS, Lambert RG, Mallon C, Buenviaje H, Pedrycz E, Luongo R, Russell AS: Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol. 2002, 29: 959-965.
PubMed
CAS
Google Scholar
Breban MA, Vignon E, Claudepierre P, Dougados M, et al: Efficacy of infliximab in severe refractory ankylosing spondylitis (AS). Results of an open label study [abstract]. Arthritis Rheum. 2001, 44: S89-10.1002/1529-0131(200110)44:10<2457::AID-ART419>3.3.CO;2-G.
Google Scholar
Munoz-Villanueva MC, E Collantes, Gratacos J, Sanmarti R, Canete JD, Gratacos J, Zarco P, Gonzalez C, Torre-Alanso JC: Successful treatment of active and refractory spondyloarthritis with the anti-TNFα monoclonal antibody infliximab. Ann Rheum Dis. 2002, 61 (suppl 1): 300-
Google Scholar
Allali F, Roux C, Kolta S, Claudepierre P, Lespessailles E, Dougados M, Breban M: Infliximab in the treatment of spondylarthropathy, bone mineral density effect [abstract]. Arthritis Rheum. 2001, 44: S89-
Google Scholar
Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sörensen H, Zeidler H, Thriene W, Sieper J: Treatment of active ankylosing spondylitis with infliximab – a double-blind placebo controlled multicenter trial. Lancet. 2002, 359: 1187-1193. 10.1016/S0140-6736(02)08215-6.
PubMed
CAS
Google Scholar
Van den Bosch F, Kruithof E, Baeten D, Herseens A, De Keyser F, Mielants H, Veys EM: Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum. 2002, 46: 755-765. 10.1002/art.511.
PubMed
CAS
Google Scholar
Brandt J, Haibel H, Reddig J, Sieper J, Braun J: Successful treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor α monoclonal antibody infliximab. J Rheumatol. 2002, 29: 118-122.
PubMed
CAS
Google Scholar
Barthel HR: Rapid remission of treatment-resistant ankylosing spondylitis with etanercept – a drug for refractory ankylosing spondylitis?. Arthritis Rheum. 2001, 45: 404-10.1002/1529-0131(200108)45:4<404::AID-ART355>3.0.CO;2-X.
PubMed
CAS
Google Scholar
Marzo-Ortega H, McGonagle D, O'Connor P, Emery P: Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum. 2001, 44: 2112-2117. 10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H.
PubMed
CAS
Google Scholar
Gorman JD, Sack KE, Davis JC: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002, 346: 1349-1356. 10.1056/NEJMoa012664.
PubMed
CAS
Google Scholar
D'Agostino MA, Breban M, Said-Nahal R, Dougados M: Refractory inflammatory heel pain in spondyloarthropathy: a significant response to infliximab documented by ultrasound [letter]. Arthritis Rheum. 2002, 46: 840-841. 10.1002/art.513.
PubMed
Google Scholar
Braun J, Sieper J: Refractory inflammatory heel pain in spondyloarthropathy: a significant response to infliximab documented by ultrasound [reply]. Arthritis Rheum. 2002, 46: 841-842. 10.1002/art.514.
Google Scholar
Banares A, Jover JA, Fernandez-Gutierrez B, Benitez del Castillo JM, Garcia J, Vargas E, Hernandez-Garcia C: Patterns of uveitis as a guide in making rheumatologic and immunologic diagnoses. Arthritis Rheum. 1997, 40: 358-370.
PubMed
CAS
Google Scholar
Samson CM, Waheed N, Baltatzis S, Foster CS: Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001, 108: 1134-1139. 10.1016/S0161-6420(01)00576-0.
PubMed
CAS
Google Scholar
Braun J, Sieper J: Infliximab in chronic uveitis [reply]. Arthritis Rheum. 2002, {See [117]},
Google Scholar
Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, Rosenbaum JT: Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001, 45: 252-257. 10.1002/1529-0131(200106)45:3<252::AID-ART257>3.3.CO;2-X.
PubMed
CAS
Google Scholar
Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B, Gallagher K, Stout T: Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 2001, 44: 1411-1415. 10.1002/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O.
PubMed
CAS
Google Scholar
El-Shabrawi Y, Hermann J: Infliximab in chronic uveitis [letter]. Arthritis Rheum. 2002,
Google Scholar
El-Shabrawi Y, Hermann J: Anti-TNFα therapy with infliximab in the treatment of HLA B27 associated acute anterior uveitis – a one year follow up [abstract]. Arthritis Rheum. 2001, 44: S425-
Google Scholar
Fries W, Giofre MR, Catanoso M, Lo GR: Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab. Am J Gastroenterol. 2002, 97: 499-500. 10.1016/S0002-9270(01)04076-X.
PubMed
Google Scholar
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001, 345: 1098-1104. 10.1056/NEJMoa011110.
PubMed
CAS
Google Scholar
Keane J, Gershon SK, Braun M: Tuberculosis and treatment with infliximab [letter]. N Engl J Med. 2002, 346: 625-626.
Google Scholar
Riminton S, Pearce N, Basten A: Tuberculosis and treatment with infliximab [letter]. N Engl J Med. 2002, 346: 625-
Google Scholar
Myers A, Clark J, Foster H: Tuberculosis and treatment with infliximab [letter]. N Engl J Med. 2002, 346: 625-10.1056/NEJMoa011858.
Google Scholar
Lim WS, Powell RJ, Johnston ID: Tuberculosis and treatment with infliximab [letter]. N Engl J Med. 2002, 346: 623-10.1056/NEJM200202213460815.
PubMed
Google Scholar
Bean GA, Rosch DR, Briscoe H, France MP, Korner H, Sedgwick JD, Britton WJ: Structural deficiences in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol mycobacterium tuberculosis infection. J Immunol. 1999, 162: 3504-3511.
PubMed
CAS
Google Scholar
Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, Vandenbroucke JP, Vandenbrouke JP: Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 1997, 349: 170-173. 10.1016/S0140-6736(96)06413-6.
PubMed
CAS
Google Scholar
Ritz MA, Jost R: Severe pneumococcal pneumonia following treatment with infliximab for Crohn's disease [letter]. Inflamm Bowel Dis. 2001, 7: 327-10.1097/00054725-200111000-00009.
PubMed
CAS
Google Scholar
Smith D, Letendre S: Viral pneumonia as a serious complication of etanercept therapy [letter]. Ann Intern Med. 2002, 136: 174-
PubMed
Google Scholar
Marotte H, Charrin JE, Miossec P: Infliximab-induced aseptic meningitis [letter]. Lancet. 2001, 358: 1784-10.1016/S0140-6736(01)06810-6.
PubMed
CAS
Google Scholar
Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL: Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc. 2001, 76: 653-656.
PubMed
CAS
Google Scholar
Zhang Z, Correa H, Bégué RE: Tuberculosis and treatment with infliximab [letter]. N Engl J Med. 2002, 346: 624-
Google Scholar
Warris A, Bjorneklett A, Gaustad P: Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001, 344: 1099-1100. 10.1056/NEJM200104053441415.
PubMed
CAS
Google Scholar
Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, Spencer-Smith EA, Goldman AL, Roth SH, Toder JS, Warner D, Quinn A, Keenan GF, Schaible TF: Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with RA. J Rheumatol. 2002, 29: 667-677.
PubMed
CAS
Google Scholar
Antoni CE, Dechant C, Haentzschel H, Alten R, Soerensen H, Schwebig A, Kalden JR, Manger B: Safety and efficacy of infliximab in 263 patients with active rheumatoid arthritis despite methotrexate therapy – a German open label trial [abstract]. Arthritis Rheum. 2001, 46: S187-
Google Scholar
Phillips K, Husni ME, Karlson EW, Coblyn JS: Experience with etanercept in an academic medical center: are infection rates increased?. Arthritis Rheum. 2002, 47: 17-21. 10.1002/art1.10243.
PubMed
CAS
Google Scholar
De Rosa FG, Bonora S, Di Perri G: Tuberculosis and treatment with infliximab [letter]. N Engl J Med. 2002, 346: 624-
Google Scholar
Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, Weinblatt M, Taborn J, Weaver A, Burge DJ, Schiff MH: Longterm safety and efficacy of etanercept in RA. J Rheumatol. 2001, 28: 1238-1244.
PubMed
CAS
Google Scholar
Kavanaugh A, Keenan G, DeWoody K, Masters P, Hendricks D, Clark J, Harriman G: Long-term follow-up of patients treated with Remicade (Infliximab) in clinical trials [abstract]. Arthritis Rheum. 2001, 46: S173-
Google Scholar
Smith KJ, Skelton HG: Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol. 2001, 45: 953-956. 10.1067/mjd.2001.117725.
PubMed
CAS
Google Scholar
Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN: Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001, 44: 2862-2869. 10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W.
PubMed
CAS
Google Scholar
van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH: Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996, 47: 1531-1534.
PubMed
CAS
Google Scholar
Robinson WH, Genovese MC, Moreland LW: Demyelinating and neurologic events reported in association with TNFα antagonism: by what mechanisms could TNFα antagonism improve RA but exacerbate multiple sclerosis?. Arthritis Rheum. 2001, 44: 1977-1983. 10.1002/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6.
PubMed
CAS
Google Scholar
Bloom BJ: Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000, 43: 2606-2608. 10.1002/1529-0131(200011)43:11<2606::AID-ANR31>3.0.CO;2-X.
PubMed
CAS
Google Scholar
Galaria NA, Werth VP, Schumacher HR: Leukocytoclastic vasculitis due to etanercept. J Rheumatol. 2000, 27: 2041-2044.
PubMed
CAS
Google Scholar
McCain ME, Quinet RJ, Davis WE: Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford). 2002, 41: 116-117. 10.1093/rheumatology/41.1.116.
CAS
Google Scholar
Shakoor N, Michalska M, Harris CA, Block JA: Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002, 359: 579-580. 10.1016/S0140-6736(02)07714-0.
PubMed
CAS
Google Scholar
Yin Z, Siegert S, Neure L, Grolms M, Liu L, Eggens U, Braun J, Sieper J: The elevated ratio of interferon-γ/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta. Rheumatology. 1999, 38: 1058-1067. 10.1093/rheumatology/38.11.1058.
PubMed
CAS
Google Scholar
Canete JD, Martinez SE, Farres J, Sanmarti R, Blay M, Gomez A, Salvador G, Munoz-Gomez J: Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon-γ is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann Rheum Dis. 2000, 59: 263-268. 10.1136/ard.59.4.263.
PubMed
CAS
PubMed Central
Google Scholar
Yin Z, Braun J, Neure L, Wu P, Liu L, Eggens U, Sieper J: Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthritis Rheum. 1997, 40: 1788-1799.
PubMed
CAS
Google Scholar
Ritchlin C, Haas-Smith S, Looney J: Production, tissue distribution and function of IL-10 in psoriatic synovium [abstract]. Arthritis Rheum. 1999, 42: S163-
Google Scholar
Claudepierre P, Rymer JC, Chevalier X: IL-10 plasma levels correlate with disease activity in spondyloarthropathy. J Rheumatol. 1997, 24: 1659-1661.
PubMed
CAS
Google Scholar
Braun J, Yin Z, Spiller I, Siegert S, Rudwaleit M, Liu L, Radbruch A, Sieper J: Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum. 1999, 42: 2039-2044. 10.1002/1529-0131(199910)42:10<2039::AID-ANR3>3.0.CO;2-6.
PubMed
CAS
Google Scholar
Rudwaleit M, Siegert S, Yin Z, Eick J, Thiel A, Radbruch A, Sieper J, Braun J: Low T cell production of TNFα and IFN-γ in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis. 2001, 60: 36-42. 10.1136/ard.60.1.36.
PubMed
CAS
PubMed Central
Google Scholar
Baeten D, Van Damme N, Van den Bosch F, Kruithof E, De Vos M, Mielants H, Veys EM, De Keyser F: Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Ann Rheum Dis. 2001, 60: 750-755. 10.1136/ard.60.8.750.
PubMed
CAS
PubMed Central
Google Scholar
Braun J, Xiang J, Brandt J, Maetzel H, Haibel H, Wu P, Kohler S, Rudwaleit M, Siegert S, Radbruch A, Thiel A, Sieper J: Treatment of spondyloarthropathies with antibodies against tumour necrosis factor α: first clinical and laboratory experiences. Ann Rheum Dis. 2000, 59 (suppl I): 10-14.
Google Scholar
Xiang J, Rudwaleit M, Thiel A, Braun J, Sieper J: Downregulation of the nonspecific and the antigen-specific T cell cytokine response in ankylosing spondylitis after treatment with infliximab [abstract]. Arthritis Rheum. 2001, 44: S236-
Google Scholar
Xiang J, Rudwaleit M, Thiel A, Radbruch A, Zhang Y, Braun J, Sieper J: Cellular immune response to the cartilage-derived autoantigen G1 of aggrecan in ankylosing spondylitis and rheumatoid arthritis [abstract]. Arthritis Rheum. 2001, 44: S236-
Google Scholar
Baeten D, Kruithof E, Van den Bosch F, De Keyser F, Veys EM: Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy. Histologic findings in eight patients from an open-label pilot study. Arthritis Rheum. 2001, 44: 186-195. 10.1002/1529-0131(200101)44:1<186::AID-ANR25>3.0.CO;2-B.
PubMed
CAS
Google Scholar
van der Heijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S: Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol. 1997, 24: 2225-2229.
PubMed
CAS
Google Scholar
Anderson JJ, Baron G, van der Heijde D, Felson DT, Felson M: ASAS preliminary criteria for short term improvement in ankylosing spondylitis. Arthritis Rheum,. 2001, 44: 1878-1886. 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F.
Google Scholar
Spoorenberg A, de Vlam K, van der Heijde D, de Klerk E, Dougados M, Mielants H, van der Tempel H, Boers M, van der Linden S: Radiologic scoring methods in ankylosing spondylitis: reliability and sensitivity to change over one year. J Rheumatol. 1999, 26: 997-1002.
PubMed
CAS
Google Scholar
MacKay K, Mack C, Brophy S, Calin A: The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum. 1998, 41: 2263-2270. 10.1002/1529-0131(199812)41:12<2263::AID-ART23>3.3.CO;2-9.
PubMed
CAS
Google Scholar
Averns HL, Oxtoby J, Taylor HG, Jones PW, Dziedzic K, Dawes PT: Radiological outcome in ankylosing spondylitis: use of the Stoke Ankylosing Spondylitis Spine Score (SASSS). Br J Rheumatol. 1996, 35: 373-6.
PubMed
CAS
Google Scholar